PATENT CLAIM ANALYSIS

Application Number: 16228310
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["558", "070000"]

Abstract:
Cell binding agent-drug conjugates comprising phosphinate-based charged linkers and methods of using such linkers and conjugates are provided.

Claim (Index 4):
The compound of  claim 1 , wherein the cell-binding agent binds to target cells which are selected from the group consisting of tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing the CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD51, CD52, CD56, CD66, CD70, CD74, CD79, CD80, CD98, CD125, CD221, CD227, CD262, CD309, CD326, CEACAM3, CEACAM5 (carcinoembryonic antigen), DLL4 (A-like-4), EGFR, CTLA4, CXCR4 (CD184), Endoglin (CD105), EPCAM (epithelial cell adhesion molecule), ERBB2 (Epidermal Growth Factor Receptor 2), FCGR1, FOLR (folate receptor,), GD2 ganglioside, G-28 (a cell surface antigen glyvolipid), GD3 idiotype, Heat shock proteins, HER1, HER2, HLA-DR10, HLA-DRB, human chorionic gonadotropin, IGF1R (insulin-like growth factor 1 receptor), IL-2 receptor (interleukin 2 receptor), IL-6R (interleukin 6 receptor), Integrins (\u03b1v\u03b23, \u03b15\u03b21, \u03b16\u03b24, \u03b111\u03b23, \u03b15\u03b25, \u03b1v\u03b25), MAGE-1, MAGE-2, MAGE-3, MAGE 4, anti-transferrin receptor, p97, MS4A1 (membrane-spanning 4-domains subfamily A member 1), MUC1 or MUC1-KLH, MUC16 (CA125), CEA, gp100, MART1, MPG, MS4A1 (membrane-spanning 4-domains subfamily A), Nucleolin, Neu oncogene product, P21, Paratope of anti-(N-glycolylneuraminic acid), PLAP-like testicular alkaline phosphatase, PSMA, PSA, ROBO4, TAG 72 (tumor associated glycoprotein 72), T cell transmembrane protein, Tie (CD202b), TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B), TPBG (trophoblast glycoprotein), TRAIL-R1 (tumor necrosis apoprosis inducing ligand receptor 1), VCAM-1 (CD106), VEGF, VEGF-A, VEGF-2 (CD309), CanAg, CALLA, and cells expressing insulin growth factor receptor, and epidermal growth factor receptor.

Metadata:
- Claim Count in Document: 19.0
- Percentile: 98.0
- Lexical Diversity: 1.1875
- Patent Class: 558.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15118726', '16228130', '16228437', '14432073', '12433604']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8505538706685454
- 35 USC 102 Novelty (BERT): 0.6940545069443186
- Combined Prediction Score: 0.8349039342961226
- Mean Citation Score: 642.8125
- Max Citation Score: 727.0148
- Similarity Product: 664.2601948230027

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test